Exelixis, Inc.

Genentech, Inc.

Symphony Evolution, Inc.

Sriram Naganathan

Matthew Pfeiffer

C Gregory Sowell

Nathan Guz

Jason Yang

Amit Srivastava

Tracy Bostick

Neel Kumar Anand

Wei Xu

Dana T Aftab

Jo Ann Wilson

Steven Lacy

Neil G Andersen

Daniel A Dickman

Linh Nguyen

JoAnn Wilson

Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.

Process for making compounds for use in the treatment of cancer

The invention relates to metabolites of cabozantinib (I) as well as uses thereof. 

Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

Dosing of cabozantinib formulations

A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and  

Process for preparing quinoline derivatives

A process for preparing a compound of Formula I is disclosed: wherein: and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and  

Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.

Human ADAM-10 inhibitors

Growing community of inventors

San Jose, CA, United States of America

Sriram Naganathan